Shots:
- Keros has dosed the first pts in P-III (RENEW) trial assessing elritercept vs PBO in adults with transfusion-dependent anemia with very low, low, or intermediate risk myelodysplastic syndromes (MDS)
- Dosing triggers a $10M milestone under Keros & Takeda’s Jan 2025 deal, in which Takeda gained global rights to develop, manufacture, & commercialize elritercept (excl. mainland China, Hong Kong, & Macau) in exchange for $200M upfront & ~$1.1B in development, commercial & sales milestones, plus tiered royalties
- Elritercept is an engineered ligand trap combining a modified activin receptor type IIA with the Fc domain of a human antibody, which is being developed to treat cytopenias, incl. anemia & thrombocytopenia, in MDS & MF
Ref: Globenewswire | Image: Keros Therapeutics| Press Release
Related News:- RIVANNA Receives the US FDA 510(k) Clearance for Accuro3S System and SpineNav-AI Image Processing Software
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
